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Background: This study evaluated tyrosine kinase receptor (TKR) expression and activation in canine pulmonary
adenocarcinoma (cpAC) biospecimens. As histological similarities exist between human and cpAC, we hypothesized
that cpACs will have increased TKR mRNA and protein expression as well as TKR phosphorylation. The molecular
profile of cpAC has not been well characterized making the selection of therapeutic targets that would potentially
have relevant biological activity impossible. Therefore, the objectives of this study were to define TKR expression
and their phosphorylation state in cpAC as well as to evaluate the tumors for the presence of potential epidermal
growth factor receptor (EGFR) tyrosine kinase activating mutations in exons 18–21. Immunohistochemistry (IHC) for
TKR expression was performed using a tissue microarray (TMA) constructed from twelve canine tumors and
companion normal lung samples. Staining intensities of the IHC were quantified by a veterinary pathologist as well
as by two different digitalized algorithm image analyses software programs. An antibody array was used to evaluate
TKR phosphorylation of the tumor relative to the TKR phosphorylation of normal tissues with the resulting spot
intensities quantified using array analysis software. Each EGFR exon PCR product from all of the tumors and
non-affected lung tissues were sequenced using sequencing chemistry and the sequencing reactions were run
on automated sequencer. Sequence alignments were made to the National Center for Biotechnology Information
canine EGFR reference sequence.
Results: The pro-angiogenic growth factor receptor, PDGFRα, had increased cpAC tumor mRNA, protein expression
and phosphorylation when compared to the normal lung tissue biospecimens. Similar to human pulmonary
adenocarcinoma, significant increases in cpAC tumor mRNA expression and receptor phosphorylation of the
anaplastic lymphoma kinase (ALK) tyrosine receptor were present when compared to the corresponding normal
lung tissue. The EGFR mRNA, protein expression and phosphorylation were not increased compared to the normal
lung and no activating mutations were identified in exons 18–21.
Conclusions: Canine pulmonary adenocarcinoma TKRs are detected at both the mRNA and protein levels and are
activated. Further investigation into the contribution of TKR activation in cpAC tumorigenesis is warranted.
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Tyrosine kinase receptorsBackground
The molecular characterization of canine lung cancer re-
mains limited compared to the more comprehensive eva-
luation of human pulmonary adenocarcinoma (hpAC). A
few similarities between the human and canine pulmonary
adenocarcinoma (cpAC) molecular signatures have been
identified and include the presence of Kirsten rat sarcoma* Correspondence: lorch.2@osu.edu
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reproduction in any medium, provided the orviral oncogene mutations and overexpression of the epi-
dermal growth factor receptor (EGFR) [1-3]. If canine
lung tumors could be classified into distinct molecular
subsets based on genomic alterations, use of targeted
therapies may improve clinical outcomes.
Tyrosine kinase receptors (TKRs) are a family of cell-
surface receptors that signal primarily through tyrosine
phosphorylation events [4]. Many TKRs have been iden-
tified as key regulators of oncogenesis. Alterations in
TKRs result in aberrant activation of their downstream
intracellular signaling pathways that are linked to cancerl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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giogenesis and metastasis. TKRs may become dysregulated
by several oncogenic mechanisms including mutations,
protein overexpression and increased gene copy number.
The established dysregulation of TKRs and their contribu-
tion to lung cancers has continued to drive the develop-
ment of drugs that block or attenuate TKR activity.
The EGFR is a TKR that has been identified as an
oncogenic driver in certain subsets of human non-small
cell lung cancer (hNSCLC). Approximately 60% of hpAC
express EGFR. As such, EGFR has become an important
therapeutic target for the treatment of these tumors. A
range of somatic mutations in the tyrosine kinase domain
of EGFR have been identified and are characterized by
short deletions in exon 19, point mutations in exons 19
and 21, single nucleotide substitutions that may occur
throughout exons 18 to 21, in-frame duplications and/or
insertions predominately in exon 20 and rarely, an exon
22 mutation. Short deletions in exon 19 and an L858R
point mutation in exon 21 account for greater than 85% of
the mutations. Mutations in the EGFR tyrosine kinase do-
main result in destabilization of its conformation and con-
stitutive kinase activity which provides continuous
activation of its downstream signaling pathways. Lung
cancers harboring constitutively active mutant EGFR are
exquisitely sensitive to EGFR tyrosine kinase inhibitors
(TKIs) with response rates reported from 27-100% [5].
Treatment for hpAC is surgical resection and adjuvant
cisplatin-based chemotherapy in combination with vino-
relbine. Primary radiation therapy is used in patients with
inoperable stage II disease or with patients that have oper-
able tumors with medical contraindications to surgery. Se-
lective patients may benefit from molecularly-targeted
therapy used in combination with chemotherapy, as a single
first line-agent or maintenance chemotherapy. The results
of standard treatment are poor as the 5-year relative
survival rate varies depending on the stage at diagnosis
from 49% to 16% to 2% for patients with local, regional
and distant stage disease, respectively [6]. Chemother-
apy for the dog has been largely unrewarding, with
minimal responses to vindesine, cisplatin, and partial
responses to vinorelbine [7,8]. No responses were seen
in dogs with primary cpAC treated with the inhaled an-
tineoplastic drugs paclitaxel or doxorubicin [9,10]. A
dog with the diagnosis of primary bronchogenic car-
cinoma was treated with the TKI, toceranib, and was
reported to have stable disease of 34+ weeks [11].
As the molecular profile of cpAC has not been well-
characterized, identification of therapeutic targets that
would potentially have relevant biological activity is impos-
sible. Therefore, the objectives of this study were to define
TKR expression and their phosphorylation state in cpAC as
well as to evaluate the tumors for the presence of potential
EGFR tyrosine kinase activating mutations in exons 18–21.Results
Sample demographics
Twelve cases of cpAC (1 necropsy sample and 11 surgical
samples) met inclusion criteria. The mean age at presenta-
tion was 11.2 years (median, 11.3; range, 8.1-15 years). Eight
of the dogs were castrated males and four were spayed fe-
males. The most represented breeds were Basset Hound,
Miniature Schnauzer, Labrador Retriever (two cases each),
and a single case from a Border Collie, Boxer, Pomeranian,
Scottish Terrier and mixed breed. Fifty percent of the dogs
(6/12) were classified as large breeds, 25% (3/12) were
medium breeds and 25% (3/12) were small breeds.
Histopathology
Tumors classified as adenocarcinomas or the recognized
subtypes were papillary 5/12 (47%), bronchioloalveolar
carcinoma 6/12 (50%) and acinar 1/12 (8%). Hematoxylin
and eosin (H&E) stained sections were used to determine
histologic differentiation. Tumors varied in their degree
of differentiation with 67% characterized as well-
differentiated, 25% as moderately differentiated and 8%
as poorly differentiated. Companion lung tissue classi-
fied as “normal” by clinical and histological appearance
was present for all 12 cases.
Selected receptor tyrosine kinase mRNA expression in
cpAC biospecimens
Reverse transcriptase-polymerase chain reaction (RT-PCR)
was used to identify the presence of cpAC mRNA of fifteen
different receptor and cytoplasmic tyrosine and serine/
threonine kinases (Table 1). Message for all the selected
TKRs and downstream serine and threonine kinases in
Table 1 was present in all of the twelve dog’s tumors
and companion normal lung biospecimens. Densitom-
etry of relative RT-PCR EGFR tumor transcripts were
significantly decreased compared to normal lung EGFR
message, whereas transcripts for ALK were significantly
increased in tumors compared to the corresponding
normal tissue ALK message (n = 3) (Figure 1).
IHC quantification of tyrosine kinase protein expression in
TMA cpAC and normal lung biospecimens
Canine pulmonary adenocarcinoma tissue microarrays
were used to discover putative TKR tumor expression
phenotypes. All cpAC and normal lung core specimens
were available for IHC analysis. Subjective classification
of immunopositivity for EGFR localization in normal lung
was determined to be in cytoplasm of the bronchial and
vascular smooth muscle, basal layer of the bronchial epi-
thelium, alveolar epithelium and the cytoplasm of alveolar
macrophages. cKIT positive staining of the normal lung
was considered moderate and found in cytoplasm of
alveolar macrophages. Normal lung PDGFRα immuno-
positivity was located in the nucleus and cytoplasm of
Table 1 Canine RT-PCR primer sets for selected tyrosine kinase receptors and signaling node kinases
Canine-specific primers used for EGFR PCR amplification of the exon gDNA
Forward Reverse
Exon 18 5′-TGAGCATTGCGGCAGTTGCT-3′ 5′-ACACCCGGAAGTCATGGAAC-3′
Exon 19 5′-GAGTGCACAGCTCTGCTCAAG-3′ 5′-GCTATCCGGGCCTGTGGACAAG-3′
Exon 20 5′-CTCTGAAGCTTTCCTCTCCCC-3′ 5′-GCGAAGTACCTGCCCTACTTT-3′
Exon 21 5′-GGCATGAACTACCTGGAAGACCG-3′ 5′-CTGTGATCTTGACGTGCTGCG-3′
Primers used for RT-PCR
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chiolar epithelium demonstrated moderate diffuse staining
of the cell membrane, cytoplasm and nucleus. Strong
immunopositivity for PDGFRβ was predominately in the
pulmonary interstitium, pneumocytes and peribronchiolar
fibroblasts of the normal pulmonary biospecimens. Faint
VEGFR2 positive reactivity was present in interalveolar
fluid of the normal lung as well as found on either side of
the pneumocytes, while positive staining for the ligand,
VEGF, was present in the cytoplasm of bronchiolar epithe-
lium and alveolar macrophages (Figure 2, left panels).
Canine pulmonary adenocarcinoma TMA cores were
subjectively graded by a board-certified pathologist using a
semiquantitative scoring scale for intensity and localization
of immunolabeling. The slides were evaluated blinded.
EGFR staining was present in the tumor cell cytoplasm
from every dog. Positivity for VEGFR2 was present in 50%
(6/12) of the patients’ tumors, whereas 100% of the tumors
were positive for VEGF. Only 25% (3/12) of the patients’
tumors were positive for c-KIT. All tumors were positive
for PDGFRα immunoreactivity and had the greatest overall
percentage of positive staining neoplastic cells. Two cpACs
had faint stromal staining for VEGF and PDGFRα whereas;
PDGFRβ had distinct strong stromal tumor staining in92% (11/12) with faint positive cytoplasmic staining and
rare membranous staining of the neoplastic cells in 75%
(9/12) (Figure 2 and Table 2).
All 12 normal and tumor tissue sets of TMA cores
were used for IHC quantification. The greatest IHC per-
cent positivity was seen for the TKR, PDGFR family. A
statistically significant increase in the percentage of
strong staining for PDGFRα was present in cpAC com-
pared to normal lung as determined by both the positive
pixel or color deconvolution algorithms. Both algorithms
also quantified a statistically significant increase in the
percentage of strong staining PDGFRβ and VEGFR2
in the normal lung cores compared to the cpAC cores
(Figure 3A-B). A greater percentage of strong staining
intensity for the growth factor VEGF was present in cpAC
biospecimens, however; the cpAC VEGF quantification
only reached statistical significance when compared to
the normal lung cores using the color deconvolution
algorithm. Quantification of the percentage of EGFR
strong immunopositivity was significantly increased in the
cpAC using the positive pixel algorithm; however, when
the measurement of percent strong positive staining
considered the entire tissue core using color deconvolu-
tion algorithm, the normal lung cores had a slightly
Figure 1 Relative TKR mRNA expression levels in canine normal lung tissue and companion lung cpAC biospecimens from three dogs.
(A) Reverse transcriptase TKR cDNA transcripts in normal lung (N) and lung cpAC (T). GAPDH serves as a loading control. (B) Densitometry: the
levels of tumor TKR cDNA normalized to total normal lung and GAPDH. Error bars, mean ± SEM. *EGFR and ALK cpAC/normal of three
dogs: P < .05.
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quantified c-KIT staining as negligible in all tissues.
Relative level of receptor and cytoplasmic tyrosine and
serine/threonine kinase phosphorylation in cpAC
biospecimens
To begin to identify which kinase families and down-
stream signaling nodes are expressed and activated in
cpAC, we evaluated the phosphorylation state of 28
TKRs and 11 downstream signaling cascades using a
slide-based antibody array. The phosphorylation status
of the TKRs and signaling nodes were determined in the
normal lung tissue and tumor for each dog (Figure 4A).
The overall mean phosphoTKR and signaling node
fluorescence intensities were greater in the cpAC when
compared to normal lung, with the cpACs having in-
creased phosphorylation of 75% (21/28) of the TKRs and
64% (7/11) of the signaling nodes (Figure 4B-D). When
considering TKR families, the strongest cpAC fluores-
cence intensities were identified in the EGFR and Insulin
R families. Phosphorylation of the fibroblast growth fac-
tor receptor, (FGFR) family was the greatest in the nor-
mal lung with phosphoFGFR3 and FGFR4 accounting
for the increased intensities. Statistically significantincreases in the phosphorylation of cpAC TKRs were
found for PDGFR, HER2, ALK, EphB1 and EphB3 and
the signaling node insulin substrate receptor-1. A sum-
mary of the percentage of biospecimens that had TKR
phosphorylation are presented in Table 3. All tumor and
normal lung biospecimens had positive fluorescence and
therefore phosphorylation of all serine and threonine
signaling nodes.
Mutational profiling of EGFR
To begin to understand if EGFR expression and activa-
tion in cpAC could be related to altered EGFR tyrosine
kinase signaling, genomic DNA for the EGFR exons, 18,
19, 20 and 21 from each cpAC and matched normal
lung biospecimens was sequenced. No mutations were
identified for any of the exons in either the non-affected
or affected lung tissues of any of the patients.
Discussion
In hNSCLC, TKRs frequently become mutated, overex-
pressed or become fusion genes as a result of chro-
mosomal translocations. These alterations perturb cell
behavior resulting in constitutive and aberrant activation
of mitogenic cellular pathways. Oncogenic TKR drivers
Figure 2 Representative micrographs of immunohistochemistry for selected TKRs and VEGF expression in TMA cores of normal lung
and cpAC samples. The tissues were probed with the antibodies for EGFR, cKIT, PDGFRα, PDGFRβ, VEGFR2 and VEGF proteins. Left set of panels:
Representative images of positive immunoreactivity for the TKRs and growth factor as shown by the brown staining in normal lung. Right set of
panels: Representative images of positive immunoreactivity for the TKRs and growth factor as shown by the brown staining in neoplastic cells
and/or stroma of the adenocarcinoma tissue. x 40; bar 50 μm.
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Table 2 Subjective scoring of TKR immunoreactivity in cpAC biospecimens from 12 dogs
TKR No staining n(%) 0 n(%) 1 n(%) 2 n(%) 3 n(%) Stromal staining n(%) Predominant localization Stained areas
EGFR 0 2 (17) 3 (25) 4 (33) 3 (25) 0 C C, M
VEGFR2 6 (50) 5 (42) 0 1 (8) 0 0 C C, M
VEGF 0 1 (8) 6 (50) 2 (17) 3 (25) 2 (17) C C, S, N
c-KIT 9 (75) 1 (8) 2 (17) 0 0 0 C C, M
PDGFRα 0 0 1 (8) 2 (17) 9 (75) 2 (17) C, N C, S, N
PDGFRβ 1 (8) 1 (8) 4 (33) 3 (25) 1 (8) 11 (92) C, S C, S, M
Result numbers (n) and percentages (%) represent number of cpAC- affected dogs. Percentage of neoplastic cells staining positive were scored as follows:
1-5% = 0, 5-25% = 1 26-50% = 2 and >50% = 3. C: cytoplasmic, M: membranous, N: nuclear, S: stromal. No staining represents number and percentage of
cpAC-affected dogs that have no evidence of any positive immunoreactivity.
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ALK, ROS1 and RET fusions, and MET amplifications.
The importance of the identification of patients with these
aberrant TKRs has led to personalized small molecule in-
hibitor therapy and thus has improved progression-freeFigure 3 Quantification of TKR immunopositivity in normal and tumo
analysis is a digitalized pixel count in a user defined region (red square) of
PDGFRα analysis (right). The bar graph represents the percent strong positive
is the number of total pixels (blue and red) minus the negative pixels (blue) in
pixels. (B) Color deconvolution analyses of IHC digitalized images accounted f
markup core of PDGFRα analysis (right) shows intensity ranges as weak positiv
staining (blue). The biospecimen percent of positive pixels strongly stained fo
represents the mean positivity of 36 tumor (black) and 36 normal (grey) TMAsurvival (PFS) rates. The findings in this study parallels
those found in hNSCLC as we demonstrate statistically
significant increases in the phosphorylation of five TKRs
and one downstream signaling node as well as increased
TKR immunohistochemical expression for four TKRs inr TMA cores using algorithm analysis software. (A) Positive pixel
each core as shown in the visual representation of the TMA core for
pixels for each TKR and VEGF (left). The fraction of strong stained pixels
the markup image of the TMA, divided by the number of total stained
or different staining densities of the entire core. The intensity range
e staining (yellow), medium (orange), strong positive (red) and negative
r TKRs and VEGF are represented in the bar graph on the left. Each bar
cores from 12 dogs. Error bars, mean ± SEM. *cpAC vs. normal: P < .05.
Figure 4 Quantification of basal TKR and signaling node phosphorylation of cpAC and normal lung tissue. (A) Representative captured
fluorescent image of a slide with four phosphorylation array profiles from paired normal and tumor protein lysates of two dogs. Differences
between tumor and normal tissue fluorescence intensities for Akt/PKB/Rac at Thr308 are highlighted in the array set from the first dog, whereas
differences between tumor and normal tissue fluorescence intensities for p44/42 MAPK are highlighted in the array set from the second dog
(white arrows). The black arrow represents one row of the array spotted with three positive (black spots) and two negative (non-colored spots)
controls. The entire array has 10 positive controls. (B-D) The protein array measured the phosphorylation status of the selected TKRs that were
evaluated using IHC as well as 24 additional TKRs and 11 downstream signaling nodes. The phosphorylation measurement of PDGFR includes pan
phosphorylation of both the alpha and beta forms of this receptor. Spot intensities were quantified using ImageQuant™ TL array analysis software. Each
bar represents the mean fluorescence intensities obtained and therefore phosphorylation of 12 tumor (black) and 12 normal (grey) normal lung lysates
from each dog. Error bars, mean ± SEM. *cpAC vs. normal: P < .05.
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ALK receptors were found in our cohort of cpAC biospe-
cimens, which recapitulates the findings in hpACs. Gene
amplification, epigenetic mechanisms and oncogenic vi-
ruses as causes of the increased TKR protein were not
evaluated in the current study.
The EGFR is a TKR whose activation is crucial for the
growth and survival of hpAC. Two studies to date have
evaluated EGFR expression using IHC in cpACs tissues
[1,12]. The localization of EGFR protein to the bronchial
epithelium and submucosal glands of the normal lung
parenchyma in the present study corresponds to the
findings of previous studies [1,12]. However in our
population of dogs, EGFR IHC positivity was also
present in both the alveolar macrophages and alveolarepithelial cytoplasm. Although human alveolar macro-
phages produce EGF in a tissue and disease-specific
manner [13,14], they do not have the EGFR receptor,
suggesting that the antibody used to detect EGFR in this
study may lack specificity to distinguish between the lig-
and and receptor as they do have protein sequence
homology at the C-terminus [15,16]. Unlike human alveo-
lar macrophages which only produce EGF, type II pneu-
mocytes of adult rats produce EGF and express EGFR
which use an autocrine mechanism that likely regulates
pneumocyte differentiation and growth [17,18].
Semiquantitative evaluation of IHC indicated that all
cpAC had immunopositivity for EGFR and therefore at
least 1-25% of the neoplastic cells had EGFR staining. The
percentage of dogs with neoplastic cell EGFR positivity in
Table 3 Percentage of cpAC and normal lung
biospecimens with TKR phosphorylation
TKR cpAC n(%) Normal lung n(%)
EGFR 11 (92) 10 (83)
HER2 12 (100) 11 (92)
HER3 12 (100) 12 (100)
FGFR1 10 (83) 9 (75)
FGFR3 10 (83) 10 (83)
FGFR4 10 (83) 9 (75)
InsR 11 (92) 12 (100)
IGF-IR 12 (100) 12 (100)
TrkA/NTRK1 12 (100) 11 (92)
TrkB/NTRK2 12 (100) 11 (92)
Met/HGFR 10 (83) 10 (83)
Ron/MST1R 11 (92) 10 (83)
Ret 10 (83) 12 (100)
ALK 11 (92) 11 (92)
PDGFR 11 (92) 10 (83)
c-KIT/SCFR 6 (50) 11 (92)
FLT3/Flk2 7 (58) 11 (92)
M-CSFR 9 (75) 11 (83)
EphA1 11 (92) 12 (100)
EphA2 11 (92) 11 (92)
EphA3 11 (92) 11 (92)
EphB1 11 (92) 10 (83)
EphB3 12 (100) 10 (83)
EphB4 11 (92) 11 (92)
Tyro-3/Dtk 11 (92) 10 (83)
Axl 7 (58) 12 (100)
Tie/TEK 12 (100) 12 (100)
VEGFR2/KDR 6 (50) 11 (92)
Phosphorylation of biospecimen protein lysate was determined by the
presence of fluorescence that was quantified after normalization to the
array spotted positive and negative controls for each sample. Each receptor
was assayed in duplicates and the mean fluorescence for that receptor was
recorded. n, represents the number of positive samples and (%) represents
the percentage out of 12 total samples.
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In a study that had 25 cases of cpAC, 80% of the tumors
expressed EGFR and of the cpACs that had EGFR, the
percentage of tumor cells counted as positive ranged
from 20-100% [1]. Genetic alterations similar to those
found in human EGFR exons were investigated by se-
quencing the tyrosine kinase domains of both the
cpACs and the non-affected tissues for detection of de-
letions, mutations or single nucleotide polymorphisms
in exons 18–21. Sequence analysis of the cpAC EGFR
TKR domains did not identify any significant nu-
cleotide substitutions. Additional genomic analysis of
cpACs for the EGFR transforming C-terminal domaindeletion mutants of exons 25 to 27 and exons 25 to 28
should be performed as these are designated as chemo-
responsive to anti-EGFR therapy [19].
The statistically significant increased phosphorylation
fluorescence intensity of the EGFR family member HER2
(ErbB2) raises the possibility of this receptor playing a
pivotal role in malignant progression. ErbB2 uniqueness
from its other family members is its inability to directly
bind any known EGF family ligand and its permanent
fixation in the constitutively active conformation. As
such, ErbB2 heterodimers demonstrate increased po-
tency in conveying extracellular signals [20]. ErbB3 does
not have intrinsic catalytic kinase activity. The most
powerful signaling heterodimer in the EGFR family is
composed of ErbB2 and ErbB3 which functions as an
oncogenic unit [21-23] capable of activating the PI3K/
Akt pathway. Novel oncogenic ErbB2 extracellular do-
main mutants have been identified in hpAC, which are
activated by elevated C-terminal tail phosphorylation or
by the formation of disulfide-linked dimers [24]. Cell
lines that overexpress ErbB2 extracellular domain mu-
tants have been shown to become potently oncogenic
and have increased cell motility [24]. The increased
phosphorylation and therefore constitutive activation
ErbB2 in cpAC provides rationale for detailed mechanis-
tic evaluation.
Approximately 3 to 7% of hNSCLC tumors are charac-
terized by rearrangement of the gene encoding anaplastic
lymphoma kinase (ALK) most commonly with echino-
derm microtubule-associated protein-like 4, resulting in
constitutively active kinases with transforming capacity
[25]. Tumors identified as having ALK fusion proteins
have a dramatic therapeutic response to specific ALK
inhibitors [26]. The small molecule inhibitor crizotinib
has demonstrated high anti-tumoral activity, significantly
higher response rate and longer PFS in ALK-positive de-
fined lung cancers. ALK phosphorylation was significantly
increased in our cpAC cohort, as were the cpAC ALK
mRNA transcripts. As IHC represents a common method
for detection of protein expression, we evaluated the TMA
for immunostaining of ALK to validate the mRNA and
phosphorylation results. Unfortunately, immunostaining
for ALK was negative using the selected antibody and
method on formalin fixed paraffin embedded samples of
canine normal lung, cpAC and the three positive control
canine tumors. However, IHC ALK staining was positive
when used on hpAC tissue section known to have an
ALK-fusion protein. IHC detection of ALK in hNSCLC
tumors presents a significant challenge due to differential
expression of ALK protein occurring at a low level and
due to the performance of current available fluorescence
in situ hybridization and IHC methods which lack sensi-
tivity and reproducibility [27,28]. To improve IHC assay
sensitivity, a novel, non-endogenous hapten, 3-hydroxy-2-
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based assay has been developed and detects low levels as
well as heterogeneous ALK protein expression in NSCLC
TMAs but it is not commercially available [27]. The
findings of increased cpAC ALK mRNA expression and
phosphorylation as well as the trend toward increased
cpAC phosphorylation of the downstream AKT and
MAPK pathways, would provide reason for speculation
that ALK may be a promoter of cpAC tumorigenesis.
The identification of significant increases in PDGFRα
protein expression and phosphorylation in cpAC may
represent a mechanism to promote angiogenesis [29,30].
PDGFRα –mediated paracrine signaling between tumor
cells and stromal fibroblasts was found to be a principal
mechanism for stroma recruitment and tumor growth
especially when tumor cells are deficient in VEGF pro-
duction [30]. The protein for the angiogenic growth fac-
tor, VEGF, was also increased in both quantitative TMA
analyses as was the phosphorylation of VEGFR2, al-
though not reaching statistical significance. The finding
of a significantly increased VEGFR2 protein by IHC in
the normal lung likely reflects the presence of vast vas-
cular capillary plexus that surrounds alveoli. Only 20%
of humans with NSCLC have increased tumor VEGFR2
expression which correlates with a highly angiogenic
phenotype. Human NSCLC angiogenesis is triggered by
a tumor VEGF/VEGFR2 autocrine feed-forward loop
which amplifies VEFG secretion by tumor cells and
when this loop is inhibited, the tumor changes to a pro-
liferative phenotype that sensitizes tumor cells to MAPK
inhibition [31]. Taken together, the data may suggest
that cpACs have activated receptors that likely contrib-
ute to angiogenesis pathways for promotion of tumor
growth and metastasis.
Conclusions
An acknowledged limitation to this work is that it is de-
scriptive in nature. The observed phosphorylation of the
TKRs and downstream effectors needs to be further vali-
dated in cpAC cell lines that are known to express these
receptors. This may be difficult as canine cpAC cell lines
are scarce. Furthermore, protein expression by IHC does
not directly correlate with a causative role in tumor
growth and survival. The observed discrepancy between
tumor IHC EGFR protein expression level could be due
to the qualitative nature of IHC with the use of an EGFR
antibody that lacked sensitivity for canine tissue, differ-
ences in sensitivities of the two digital positive pixel
quantification algorithms, as well as, the subjective de-
termination of the staining by the pathologist. Further-
more, the samples used for the tumor lysates were not
microdissected and thus contain tumor, stroma and
non-neoplastic cell infiltrates. When comparing receptor
mRNA and protein levels in a tumor to “histologicallynormal lung” tissue within the same individual, it is pos-
sible that molecular pathology has preceded the develop-
ment of morphologically identifiable changes through the
“field of cancerization” effect. As such, the normal tissue
may have been in a precancerous state diminishing the
possibility of finding differences. Although we found no
evidence of mutations or significant single nucleotide
polymorphisms in the selected EGFR exons that were
sequenced from the normal lung tissues when compared
to the NCBI canine reference gene, we are unable to defin-
itively state that the “normal” lung tissue was not in a mo-
lecularly significant pre-neoplastic state for every receptor
evaluated in this study. The inability to detect statistically
significant differences in many of the TKRs at the protein
and phosphoprotein levels may have been affected by the
power of the study. If differences in the number of the
receptors between the normal lung and the cpAC were
relatively large, the power would be less affected however,
given the heterogeneity of tumors it may be that the
number of primary cpACs used was not sufficient to
find a statistically significant result. Finally, the multi-
plexed phosphorylation TKR assay is labeled for human
phosphorylation receptor detection as only approxi-
mately 50% of the phosphotyrosine receptor antibodies
have been validated for canine use. Thus, the use of
this comprehensive screening array could potentially
have a lower sensitivity and specificity in our patient
population.
Nevertheless, this work establishes that cpAC TKRs are
detected at both the mRNA and protein levels and are
activated. Although this study analyzed a limited number
of samples, the results expand our cpAC knowledge and
indicate that much work is still needed in this field.
Methods
Case inclusion and exclusion criteria
The medical records of all dogs with a diagnosis of pri-
mary cpAC were reviewed to acquire signalment, clinical
and pathological diagnosis data. All dogs with a clinical
diagnosis of cpAC had H&E stained slides made from
recuts of their formalin-fixed, paraffin embedded tissue
blocks for evaluation by a third veterinary anatomic
pathologist (CP). This pathologist’s evaluation was used
to confirm the previous diagnosis of cpAC. Patients in-
cluded in this study were diagnosed with cpAC and had
been evaluated during a five-year period (2007–2012).
Study inclusion criteria were a clinical and pathological
diagnosis of primary lung cpAC, the patient was stable
enough to undergo a lung lobectomy and consent had
been given by the owner to collect tissue specimens for
the biospecimen repository. Exclusion criteria included
chemotherapy prior to tumor resection, evidence of other
neoplasia, unstable clinical disease and lack of consent to
collect tissues.
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Canine pulmonary adenocarcinoma tissue specimens
were obtained from cases that presented to The Ohio
State University Veterinary Medical Center (OSU-VMC).
Owner consent to allow tissue collection was obtained in
accordance with the approved IACUC protocol. Samples
were obtained during surgery and snap frozen in liquid ni-
trogen within 15 minutes of harvest and stored at −80°C.
Tissue was also placed in formalin and processed for rou-
tine paraffin embedding for evaluation of H&E stained
sections. Tissue was cataloged and banked in the OSU-
VMC Biospecimen Repository. A total of 12 primary lung
adenocarcinomas with paired normal lung tissues from
the same dog were used. A de-identified human lung
adenocarcinoma was obtained from the National Cancer
Institute Cooperative Human Tissue Network Biospe-
cimen Repository under The Ohio State Cancer Insti-
tutional Review Board approved protocol 2011C0112
and was used as a positive control for ALK gene trans-
location. Routine biomarker testing was performed for
the presence of ALK translocation using fluorescent in
situ hybridization with the FDA-approved Vysis ALK
Break- Apart FISH Probe Kit (06 N38-020, Abbott
Molecular, Del Plaines, IL) which is optimized for
identifying and quantifying rearrangements of ALK
gene from formalin-fixed, paraffin-embedded hNSCLC
tissue specimens. The sample was considered positive
as >25 cells out of 50 had positive fluorescence as vali-
dated by both a pathologist as well as semi-automated
scanning imaging analysis software.
RNA isolation and reverse-transcriptase polymerase chain
reaction
Total RNA was isolated from dog lung tissue and cpAC
tumors using the Absolutely RNA Miniprep Kit (Strata-
gene, La Jolla, CA) according to the manufacturer’s in-
structions. The quality and quantity of the RNA was
determined spectroscopically using a NanoVue Spectro-
photometer (GE Healthcare, Piscataway, NJ). TaqMan®
Reverse Transcription kits (Applied Biosystems, Carlsbad,
CA) were used to make cDNA for RT-PCR analysis of all
transcripts of the genes. Primer sequences used for RT-
PCR reactions are listed in Table 1. Gel electrophoresis
was used to separate the amplified cDNA products ac-
cording to size. Amplicons were resolved on a 1% agarose
gel to visualize the products. Densitometry measurements
of each cDNA band were determined. Data were normal-
ized by determining the ratio of the target cDNA concen-
tration to GAPDH to correct for differences in RNA
quantity between samples. Each of the three dogs normal
and tumor transcripts were evaluated in triplicate for each
gene. ImageQuant™ TL Analysis software version 7 (GE
Healthcare, Piscataway, NJ) was used for densitometric
quantification.DNA extraction and PCR of EGFR
DNA from all dog lung tissue and cpAC tumors was pre-
pared using the DNeasy Blood and Tissue Kit (Qiagen,
Valencia, CA) according to the manufacturer’s instruc-
tions. General PCR conditions used to amplify EGFR were
an initial denaturation at 95°C for 2 min, 32 cycles of de-
naturation at 97°C for 30 s, annealing at 65°C for 60 s, and
extension at 72°C for 90 s followed by elongation at 72°C
for 7 min and terminated at 4°C. All amplifications
used a high fidelity polymerase (Platinum Taq HiFi
Polymerase, Invitrogen, Carlsbad, CA). Primers are
listed in Table 1.
Sequencing and sequence alignment
Standard PCR was used to generate high fidelity Taq
polymerase-amplified PCR products. Amplicons were re-
solved on a 1% agarose gel to visualize the products. The
resolved PCR products were extracted from the gel,
purified using QIAquick PCR Purification kit (Qiagen,
Germantown, MD) and sent for sequencing. Each exon
and PCR product was sequenced using BigDye™ Termin-
ator Cycle Sequencing chemistry (Applied Biosystems,
Carlsbad, CA). Sequencing reactions were run on an Ap-
plied Biosystems 3730 DNA Analyzer automated sequen-
cer. Sequence alignments were made to the reference
sequence NCBI: EGFR epidermal growth factor receptor
[Canis lupus familiaris (dog)]Gene ID: 404306, updated
on 19-Oct-2013) using the ClustalW procedure in DNAS-
TAR Software v MegAlign™ 5.06, Madison, WI.
Tissue microarray and immunohistochemistry
An anatomic pathologist (CP) reviewed the H&E stained
slides for each dog and selected three representative sites
of the cpAC tumor and normal lung to be used for the
construction of the tissue microarray (TMA). The corre-
sponding sites from the H&E slides were then matched to
the paraffin embedded tissue block, 2 mm cores were ex-
tracted and placed into the predetermined sites on the
TMA recipient blocks. A computer-controlled autostainer
as above (Dako, model S3400, Carpinteria, CA) was used
to carry out the immunostaining. Immunohistochemistry
staining was performed for EGFR (Santa Cruz Biotechnol-
ogy, Inc., #sc-03; 1:500) [32,33], canine stem cell factor
receptor (CD117/c-kit; Dako #A4502; 1:250) [34], platelet-
derived growth factor receptor alpha (PDGFRα; Santa Cruz
Biotechnology, Inc., #sc-338; 1:50) [35], platelet-derived
growth factor receptor beta (PDGFRβ; Biogenex, #Nu483-
uc; 1:200) [36], vascular endothelial growth factor
receptor two (KDR/Flk-1/VEGFR2; Santa Cruz Biotech-
nology, Inc., #sc-6251; 1:50) [37,38], vascular endothe-
lial growth factor (VEGF; Santa Cruz Biotechnology,
Inc., #sc-152; 1:200) [39] and anaplastic lymphoma kin-
ase (ALK; Cell Signaling Technology, #3633; 1:50).
Slides were rinsed in wash buffer and incubated with
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mouse antibodies diluted to 1:200 in protein block for
30 min and rinsed in wash buffer. The slides were incu-
bated for 30 min in an avidin/biotin-based peroxidase
system to allow detection of biotinylated antibodies
(VECTASTAIN® Elite® ABC System, Vector Laboratories
INC, Burlingame, CA). Tyrosine kinase receptor and
VEGF positive controls for the TMA IHC were single tis-
sue cores of canine melanoma, prostate adenocarcinoma
and apocrine gland anal sac adenocarcinoma. The selected
TKRs and VEGF have been previously identified in these
canine tumor types or from tumor-derived cell lines
[40-43]. Canine lung served as the positive control for ex-
pression of EGFR protein [1]. Negative controls were ir-
relevant isotype matched antibody at matched dilutions.
Immunohistochemistry quantification and scoring
Quantification of IHC staining was performed on digita-
lized TMA slides by Aperio ScanScope XT, (Aperio
Technologies, Vista, CA) and by semiquantitative grad-
ing by a veterinary pathologist. Image analysis was per-
formed using two different Aperio algorithms. The first
IHC quantification analysis was done using positive pixel
count v.9 algorithm counts and quantifies the amount of
stain of a specific color set by the user base on the HIS
(hue, saturation, intensity) color model. The algorithm
output provided a number of 1+, 2+ and 3+ intensity
positive pixels and the number of total pixels in each an-
notated layer. Total number of pixels consisted of posi-
tive and negative pixels excluding white area of the
virtual slides (i.e., the center of bronchi and alveoli). The
results are reported as positivity which is the total num-
ber of positive pixels/total number of pixels. Briefly,
positive pixel counts (PPC) were obtained for a square
area of 393598 μm2 at a magnification of 20X for all the
tumor and normal lung cores. For each dog, the PPC
obtained from each of the three tumor cores was nor-
malized to the PPC from each of the three normal lung
cores. The normalized PPC from each of the 12 dogs
was used to calculate the overall IHC PPC value for the
receptor or growth factor. Color deconvolution was the
second algorithm used for IHC quantification. This algo-
rithm separated the image into channels based on normal-
ized optical density and then overlapped these channels
and evaluated the entire tissue core area of each sample.
Normalized optical density was derived from the control
DAB stained and unstained lung tissues used in each indi-
vidual automated IHC processor staining run.
The subjective quantitative scoring of positive or nega-
tive immunoreactivity of cells and stroma within the
cores was performed by a veterinary pathologist. Per-
centage of neoplastic cells staining positive were scored
as follows: 1-5% = 0, 5-25% = 1, 26-50% = 2 and >50% = 3.
Location of staining was also noted as cytoplasmic (C),membranous (M), nuclear (N), and stromal (S). Specimens
that had no IHC staining were designated as having “no
staining”.
Protein isolation
Forty grams of either whole lung tissue or tumor were
placed in a gentleMACS™ M tube (Miltenyi Biotec,
Auburn, CA), with 400 μL of 1x cell lysis buffer (Cell
Signaling, Danvers, MA), 1 mM PMSF and protease in-
hibitors (Halt protease inhibitor cocktail kit, Pierce,
Rockford, IL, USA), homogenized with a gentleMACS™
dissociator (Miltenyi Biotec, Auburn, CA) and then cen-
trifuged for 5 min at 4,000 × g at 4°C. The supernatants
were collected and protein concentration determined by
a modified Bradford method (Bio-Rad Laboratories, Inc.,
Hercules, CA). Lysates were stored at −80°C.
Tyrosine kinase receptor analysis
For analysis of tyrosine kinase receptor phosphorylation, a
human PathScan® TKR signaling array was used according
to the manufactures instructions (Cell Signaling, #7949,
Danvers, MA). The TKR signaling array is a slide based
antibody array that allows for the simultaneous detection
of 28 tyrosine kinase receptor and 11 important signaling
nodes when phosphorylated at tyrosine or other residues,
10 positive and two nonspecific IgG negative controls.
Each TKR is spotted on the array in duplicates. A total of
150 μg of protein was used for each array pad. A biotinyl-
ated detection antibody cocktail followed by a streptavidin-
conjugated DyLight 680® was used to visualize the bound
detection antibody. Arrays were developed by fluorescent
imaging and captured with a digital imaging system. Spot
intensities were quantified using Typhoon™ 9410 and
ImageQuant™ TL Array Analysis software version 7 (GE
Healthcare, Piscataway, NJ). Mean fluorescence intensities
for each TKR and signaling node were determined from
the 12 cpAC and normal lung tissue lysates.
Statistical analysis
Differences in the RT-PCR relative tumor and normal lung
tissue cDNA densitometry values for the paired samples
from three dogs and IHC pixel analyses values from all
12 dogs were assessed using a Wilcoxon matched-pairs
signed- rank test for nonparametric analysis. Likewise,
mean fluorescence intensities for each TKR and signaling
node from the 12 dogs provided a small data set thus giv-
ing little power to detect non-Gaussian distributions and
therefore were evaluated using a nonparametric analysis of
Wilcoxon matched-pairs signed- rank test which assumes
that the differences in groups are distributed symmetric-
ally around their median. The confidence level was set at
95%. Significance was set at P < 0.05. Tests were executed
with Prism® v.6.02 for Windows (GraphPad Prism®, La
Jolla, CA).
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